A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration-Reference-Cited by-同舟云学术

A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration

Published:2022-07 Issue: Volume:239 Page:180-189
ISSN:0002-9394
Container-title:American Journal of Ophthalmology
language:en
Short-container-title:American Journal of Ophthalmology

Author:

Poor Stephen H.^ORCID,Weissgerber Georges,Adams Christopher M.^ORCID,Bhatt Harit,Browning David J.,Chastain James^ORCID,Ciulla Thomas A.^ORCID,Ferriere Michael^ORCID,Gedif Kinfemichael,Glazer Louis C.,Joondeph Brian C.^ORCID,Normand Guillaume^ORCID,Sheth Veeral^ORCID,Watters Christie,Grosskreutz Cynthia L.

Funder

Novartis AG

Novartis Pharmaceuticals Corporation

Publisher

Elsevier BV

Subject

Ophthalmology

Reference21 articles.

1. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis;Wong;Lancet Glob Health,2014

2. Characterizing disease burden and progression of geographic atrophy secondary to age-related macular degeneration;Chakravarthy;Ophthalmology,2018

4. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six–week results of the VIEW studies;Schmidt-Erfurth;Ophthalmology,2014

5. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study;Brown;Ophthalmology,2009

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor Inhibitors in Health and Disease;Pharmaceuticals;2024-07-18

2. Treatment avenues for age-related macular degeneration: Breakthroughs and bottlenecks;Ageing Research Reviews;2024-07

3. Drug-like properties of tyrosine kinase inhibitors in ophthalmology: Formulation and topical availability;International Journal of Pharmaceutics;2024-04

4. Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis;Frontiers in Pharmacology;2024-01-04

5. Acrizanib as a Novel Therapeutic Agent for Fundus Neovascularization via Inhibitory Phosphorylation of VEGFR2;Translational Vision Science & Technology;2024-01-02